These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population. Scobie MR; Zhou KI; Ahmed S; Kelley MJ JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430 [TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y Front Immunol; 2022; 13():1030969. PubMed ID: 36426352 [TBL] [Abstract][Full Text] [Related]
5. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients. Hu X; Guo J; Shi J; Li D; Li X; Zhao W BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743 [TBL] [Abstract][Full Text] [Related]
6. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Coleman S; Xie M; Tarhini AA; Tan AC Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709 [TBL] [Abstract][Full Text] [Related]
7. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma. Andrews MC; Li G; Graf RP; Fisher VA; Mitchell J; Aboosaiedi A; O'Rourke H; Shackleton M; Iddawela M; Oxnard GR; Huang RSP JCO Precis Oncol; 2024 Jun; 8():e2300640. PubMed ID: 38848517 [TBL] [Abstract][Full Text] [Related]
8. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604 [TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432 [TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. Moeckel C; Bakhl K; Georgakopoulos-Soares I; Zaravinos A Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047684 [TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes. Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346 [TBL] [Abstract][Full Text] [Related]
12. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342 [TBL] [Abstract][Full Text] [Related]
13. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. Zhang L; Han X; Shi Y JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327 [TBL] [Abstract][Full Text] [Related]
14. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M Front Immunol; 2021; 12():751407. PubMed ID: 34659255 [TBL] [Abstract][Full Text] [Related]
15. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572 [TBL] [Abstract][Full Text] [Related]
16. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351 [TBL] [Abstract][Full Text] [Related]
17. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016 [TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449 [TBL] [Abstract][Full Text] [Related]
19. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy. Miao YR; Liu CJ; Hu H; Yang M; Guo AY Cells; 2022 Sep; 11(18):. PubMed ID: 36139377 [TBL] [Abstract][Full Text] [Related]
20. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q Front Immunol; 2021; 12():798474. PubMed ID: 35087523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]